Protein reference materials are traditionally prepared by purification from mammalian or human tissues. The supply of these tissues is limited; consequently, there is a growing need for applied molecular and cellular biology technologies for the production of human recombinant proteins. This is especially true when only small amounts of the proteins are available in the tissues. We review the current knowledge necessary for high-level production of such proteins in different heterologous expression systems, using our data on y-glutamyltransferase (EC 2.3.2.2) as an example. We describe the steps required to achieve the expression of enzymes and other proteins in Escherichia coli, yeast, or mammalian cells. We list many of the problems investigators may face in preparing recombinant proteins, and provide information on selecting the most appropriate system as well as the most favorable experimental conditions. Depending on the expression system, recombinant proteins can potentially be obtained for most, if not all, enzymes of interest in clinical chemistry, and such proteins should possess characteristics very similar to those of the corresponding human native proteins. Studies suggest that these products can be used as reference materials in clinical chemistry laboratories.
Protein reference materials are traditionally prepared by purification from mammalian or human tissues. The supply of these tissues is limited; consequently, there is a growing need for applied molecular and cellular biology technologies for the production of human recombinant proteins. This is especially true when only small amounts of the proteins are available in the tissues. We review the current knowledge necessary for high-level production of such proteins in different heterologous expression systems, using our data on y-glutamyltransferase (EC 2.3.2.2) as an example. We describe the steps required to achieve the expression of enzymes and other proteins in Escherichia coli, yeast, or mammalian cells. We list many of the problems investigators may face in preparing recombinant proteins, and provide information on selecting the most appropriate system as well as the most favorable experimental conditions. Depending on the expression system, recombinant proteins can potentially be obtained for most, if not all, enzymes of interest in clinical chemistry, and such proteins should possess characteristics very similar to those of the corresponding human native proteins. Studies suggest that these products can be used as reference materials in clinical chemistry laboratories.
In clinical chemistry laboratories, measurements of enzyme activity must be reproducible from one laboratory to another, as well as in the same laboratory over time. To maintain the success of a recommended method and to prevent a return to a profusion of unrelated methods of enzyme analysis, enzyme reference materials are needed. The results of secondary or modified enzyme methods can then be traced back to a recognized primary method. The qualities required for an enzyme reference material include tested and predictable stability of catalytic activity and an activity in the selected method (or methods) that is assured within definite limits. Catalytic properties of the reference material must be as close as possible to those of the human enzyme. This strate was developed in Europe (6) and in the US (7) . Reference materials exist or are in the process of being prepared ( Table 1) .
The first indication of a demand for genetically engineered production systems appeared for proteins of human origin that were available in limited quantities. However, such systems found broader applications as human tissues became more and more difficult to obtain, because of their use in transplantation or because of clinical or ethical limitations.
Possible contamination of human material by viruses and transmissible diseases further restricted the possible sources. Recent technologies have been oriented to the control of the subcellular location of the recombinant protein in the host cell for purification purposes. Many studies were performed to develop sophisticated production systems to overcome these problems, with the ultimate advantage of providing better-defined proteins with no batch-to-batch variation influencing physicochemical and catalytic features of the purified products.
For these reasons, we initiated, in 1986, with the support of the EC BCR (Community Bureau of Reference of the European Communities, Brussels, Belgium), 
11). GGT is a plasma membrane-anchored glycosylated protein that is widely distributed in various cells and body fluids (12). It is expressed as a unique precursor that is further cleaved into two nonidentical subunits. In clinical chemistry and clinical pharmacology laboratories,
GGT activity is measured in plasma and used as a marker for chronic alcoholism (13, 14) , hepatobiliary diseases, hepatocarcinogenesis (15) , and as an indirect marker for enzyme induction by drugs (16).
StrategIes and TechnologIes
The biosynthesis of a heterologous protein in host cells relies upon several steps that must resemble as much as possible those normally occurring in the original cells (Figure 1) . Depending on the expression strategy, the final product will exhibit a greater or lesser similarity to the natural protein, in terms of physicochemical, immunological, or catalytic properties. In general, the expression of a cDNA (see Glossary) or a gene requires prior determination of the problems associated with synthesis of the corresponding protein and the degree of homology (in comparison with the original protein) required for its further utilization. Thus, there are no universal rules that can be followed, and investigators must consider and optimize each of several steps that are commonly encountered.
It may be helpful to the reader, then, to consider the general scheme depicted in Figure 2 as a common thread for the items discussed in this article.
To achieve high-level expression, one must adopt a strategy based on the purpose of the experiment and the type of protein to be produced. Before choosing an expression system, it is important to consider the type of protein to be produced. Besides its origin, many features need to be analyzed: its size, its subcellular location, and the amount of posttranslational modification that normally occurs during its maturation, e.g., glycosylation, phosphorylation, formation of disulfide bonds, or proteolytic cleavage.
In this review, we analyze the features of several production systems and summarize our approaches to the production of GGT, using this enzyme as an example for the design of strategies to produce other human enzymes or peptides, especially those of interest in clinical chemistry.
Subcloning Strategies
Whatever the expression system is, the first step is to subclone the coding sequences into an appropriate expression vector. For a eukaryotic protein, a cDNA without introns is preferred, rather than the whole gene, for constructing the plasmid that will be used to transfect the host cells. The use of intronless cDNA is especially important when the protein is to be expressed in E. coli, in which splicing events do not occur.
Special attention must be paid to the untranslated regions of the cDNA that flank the coding sequences. They may contain regulatory elements that are active The DNA sequence to be expressed must be correctly inserted into the vector, downstream from the promoter that will control its transcription levels. It is necessary to determine the location of restriction endonuclease cleavage sites on the DNA fragment with respect to known cloning sites on the expression plasmid. Restriction sites can also be created by specific modifications of the nucleotide sequence. However, it may be necessary to veri.fr the structure and even the nucleotide sequence of the final vector before continuing the experiment, to make sure that no undesired mutation has been introduced in the coding region.
Expression in E. coil
This Gram-negative bacterium, the most widely used expression system for a variety of proteins, has been extensively characterized with regard to its genetics and physiology and offers many advantages. Thus E.
coli is the first choice for the production of any protein. Protein folding, either in prokaryotes or in eukaryotes, is the subject of an interesting review by Gething and Sambrook (45) . These authors focus on the importance of highly conserved molecular chaperones and several heat-shock and stress-induced proteins that maintain the polypeptides as relatively unfolded precursors before translocation across membranes and also determine the eventual native conformation.
It is difficult to predict how efficient host cells can be with regard to the folding of a heterologous recombinant protein. However, it may be possible to solve the problem of producing active recombinant proteins by assisting folding either by coexpressing the appropriate molecular chaperone in the host cell (46), or by in vitro renaturation in the presence of this chaperone (47) . Thus, formation of a correct tertiary structure is a decisive step in the production of a recombinant protein.
It is also an absolute requirement for any product that is to be introduced into the original organism, since structural dis&milsirities can result in immunogenicity. An identical problem can result from the presence of formylmethionine (48) When designing a system to produce a fusion protein, investigators must bear in mind that they will eventually need to perform site-specific cleavage if the protein is required as a native gene product. This step, realized by using either proteolytic enzymes (e.g., trypsin, collagenase, enterokinase, or subtilisin) or chemical cleavage (e.g., with cyanogen bromide), may substantially decrease the productivity rate.
Potential host strains and appropriate fermentation
conditions. When designing an expression system, investigators must focus not only on the vector, but also on the bacterial strain, some functions of which are important for high-level expression. Special attention must be given to the genotypic features of tested host cells. Besides the genetic properties of the host, the strain has to be selected on the basis of growth requirements (e.g., nutrients, temperature, and oxygen content, which determine the costs of the fermentation) and the mode of promoter induction: (67) . Unlike bacteria, yeasts allow the possibility of integration of a vector into a specific site of its genome, ' (mmol/L)wereapparentaffinity constantsfor the standarddonor (y-glutamyl-3-carboxy-4-nitroanilide) and acceptor (glycyl-glycine).l,, and pH, values werethe average of two or three independent determinations in cell extracts (61) .
b Cells were cultured in the presence of sodium butyrate. ND, notdetermined in the corresponding literature cited. GOT was produced as a mature enzyme, with specific activity higher (-250 U/g protein) than that of the enzyme synthesized in E. coli (Table 2) , which facilitates its purification.
Expression in Mammalian Cells
As demonstrated above, high-level expression of heterologous genes can be achieved only after numerous steps have been optimized. This means that success is never assured, whatever the system. As mentioned earlier, if almost all bacterial and yeast genes can be expressed without major problems in a homologous system or in E. coli, the choice of the appropriate system for expressing higher eukaryotic genes or cDNAs is a little more complicated, since every system discussed in this article can provide interesting features that make the product useful either for structural and functional studies or for eventual industrial or therapeutic applications. However, if the eukaryotic gene product has to resemble as much as possible the natural protein-for example, when it is to be used as a drug, a reference material, or a reagent in a kit-it is necessary to utilize a system capable of maturing the produced polypeptide chain correctly, such as mammalian cells. In that case, investigators should always keep in mind the sugar chains, which can potentially result in additional immunogenicity.
A mammalian cell used as host for the expression of a higher eukaryotic gene also provides the 
Promoters.
Most of the promoter systems function as constitutive elements and are derived from SV4O and adenovirus.
They are associated with viral transcriptional enhancers that are responsible for host cell preferences, assuming that they are the likely primary determinants in the tissue specificity of gene expression. mRNA translation.
As described for expression in S. cereuisiae, translation initiation occurs after binding of the ribosome at the 5' end of the mRNA and scanning on the molecule until an initiation codon AUG is located. A purine is required at the -3 position, and it is known that secondary structure around this region has a negative influence.
Thus, when preparing the cDNA inserts, C and G nucleotides should be avoided if synthetic linkers have to be designed for subcloning purposes. Furthermore, it is better to remove as much as possible of the 5' and 3' untranslated regions, which potentially reduce translation efficiency and mRNA stability, respectively.
Choice of eukaryotic cell line for stable expression.
Special attention must be given to the choice of the cell line that will be used as the host system. The first obvious point concerns the amount of expression of the corresponding endogenous protein. Not only must this amount be as low as possible, but also the host protein must differ from the recombinant one in its physicochemical or catalytic properties. It is essential that the endogenous protein not interfere with the recombinant product during the activity assay or during purification of the latter.
The second element to consider is the growth of the selected cells. Cell lines showing no special sensitivity to serum are preferred in order to avoid problems in adapting the cells to a new serum batch when the previous one has been used up. Eventually, serum-free medium will be the best solution. It is also important to choose cells that grow fast, assuming that the doubling time under optimal conditions can vary from 10 h to a few days, depending on the cell line. This is particularly crucial to reduce the time necessary for high-scale production of the recombinant protein. These two criteria were examined when we selected the convenient host cell line for production of human GGT. Chinese hamster lung V79 cells were chosen for transfection:
The endogenous GGT levels were not detectable and the doubling time was -10.4 h (94).
Finally, when the recombinant product is a glycoprotein, it may be of interest to know how the cell glycosylates its proteins. Because of their location, oligosaccharide chains may affect the activity of the glycoprotein, its tertiary and quaternary structures, its stabffity, its antigenicity, and its targeting. Therefore, specific information must be obtained, e.g., regarding the activity of some of the enzymes involved in glycosylation, such as those of al-6-fucosyltransferase and N-acetylglucosaminyltransferases (95), which are involved in trimming the molecule with complex or triand tetraantennary chains that can modify the properties of the resulting glycoprotein.
Optimization of the cell culture. Since cell culture is a time-consuming and somewhat expensive technology, it is often advantageous to optimize a few simple steps of the experimental procedures.
The first factors to consider are the cryopreservation and maintenance of cells. These techniques are essential in many biotechnology industries, including human fertility or transplant services. Liquid nitrogen is the most convenient cryogen (-196#{176}Cunder atmospheric pressure), even though formation of free radicals and nucleic acid damage caused by ionizing radiation cannot be completely provented (96). Also, the rate of cooling may significantly alter survival after cryopreservation.
Thus, the cooling rate and the formulation of the cryoprotectant must be optimal. However, surviving cells will commonly have various degrees of damage, showing, even after repair, alterations in either structure or function. Quality controls must therefore be used after thawing to assess the recovery of the cells on the basis of several of their important characteristics for expression of the desired function.
The second element that has to be examined is the selection of an optimal formulation of the culture medium for each cell line. Commercially available media can be used as a preliminary approach, and additional or alternative nutrient effects must be screened in the presence of a minimal amount of serum. Cell lines frequently used as transgenic hosts can now be cultured in ready-to-use media with low serum concentrations that are optimized for each line. Serum-free medium should be the ultimate goal: it is chemically defined, shows no batch-to-batch variation, and has no undesired effects due to serum hormones.
Eventually to that reported for the kidney, the tissue containing the highest GGTspecific activity in all mammals (Table 2) . Not surprisingly, the enzyme was histochemically detected at the external side of the plasma membrane of the transfected V79 cells.
The "light" form of the recombinant GOT (lacking its N-terminal anchorage peptide cleaved by papain) was purified to homogeneity and extensively characterized. It was expressed as a heterodimer, as in human tissues. This suggests that V79 cells express a proteolytic enzyme capable of cleaving GGT into its two normal subunits.
Structural analyses were performed in deglycosylation experiments, showing that the recombinant GOT was highly glycosylated, with the sugar moiety corresponding to >40% of its molecular mass, as estimated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis.
However, the glycosylation potential of V79 cells is not a hindrance, since the catalytic properties (Km5, optimal pH) of the recombinant GOT were almost identical to those of human serum and hepatoma Hep G2 GOTs (61). Therefore, depending on further characterization data, recombinant human GOT produced in V79 cells may well be a good candidate for an enzyme reference material.
V79 cells seem to offer good host specificities for stable high-level expression of human proteins. Attempts to increase the production of recombinant GOT by optimization of cell culture conditions (medium formulation, additional nutrients, culture method) are currently in progress in our laboratory.
For instance, by treating the transfected V79 cells with sodium butyrate in culture,
we recently increased the GOT specific activity to >8 kU/g protein (62).
Similar GOT expression levels were recently obtained in Chinese hamster ovary cells transfected by electroporation of a plasmid containing human Hep G2 GOT cDNA under the control of the cytomegalovirus promoter and cultured for high-level production (63). Cells naturally expressing high protein activities. This system differs from the previous ones in that it does not utilize any gene transfer step. It consists of a systematic screening of various cell lines or tissues naturally expressing high amounts of the endogenous protein. In our laboratory, the production of GOT was studied in human hepatoma cell lines such as Hep G2 or PLC/PRF/5 ( Table 2) . Though adapted to mass cultures on microcarriers (63, 64) , these cells had a highly regulated, relatively low level of endogenous GOT expression (70 to 90 U/g protein).
Other Expression Systems
The use of such a system may offer the tremendous advantage of providing the exact enzyme desired, with identical structural and functional specificities, and the correct conformation.
However, production of endogenous proteins may also be limited by the existence of regulatory mechanisms involved in the expression control of the corresponding gene in the cell that are usually not occurring when the gene is heterologously expressed.
Nonetheless, after screening and careful selection of the cells for homologous expression, no molecular biology and cell transfection experiments are needed. Thus, using this system could be an easy, inexpensive, and interesting preliminary strategy.
Discussion
The need for a "stable enzyme preparation of known were adopted by the European Pharmacopoem.
Regarding enzymes of importance in clinical chemistry, several reference materials have already been certified (Table 1) . However, they were all obtained by classical methods, i.e., purification from mammalian or human tissues. For example, our certified GOT batch was prepared from pig kidney (10, 11).
Since then, in our laboratory, GOT has been used for studying the feasibility of molecular or cellular biology technologies to produce a human reference material. Figure 2 illustrates the steps followed during the course of these experiments and summrnizes the essential problems. We simultaneously studied the expression of endogenous GOT in human hepatoma cell lines, namely, Hep G2 and PLC/PRF/5 (61). The activity levels were relatively low (Table 2) , making the preparation of an enzyme fraction purified from these cells rather difficult as well as expensive. Thus, heterologous expression of human GOT has been studied in different systems (21, 22, 61, 63) . These experiments provided several important data regarding catalytic requirements as well as structural features. The high levels of expression in the transfected V79 cells were particularly important. We now possess a very efficient production system that is and will be extremely useful, not only as a source of a standard enzyme reference material, but also for basic research, providing large amounts of recombinant human enzyme to study the structure-function relationships of human GOT.
Other enzymes whose activities are measured in clinical chemistry laboratories have been expressed in different heterologous systems, as summarized nonexhaustively in is the ability to measure the enzymatic activity of both recombinant and native enzyme under the same optimal conditions. Special consideration must be given for proteins whose contents in biological fluids are determined by immunochemical techniques. The iinmunological recognition of these antigens can be affected if the folding or physicochemical characteristics of the recombinant proteins have been modified when synthesized in a particular host cell. 
Glossary
Antitermination element: usually a protein that allows RNA polymerase to transcribe through certain transcription terminator sites. cDNA DNA complementary to an RNA, synthesized from it by in vitro reverse transcription. Electroporation: a method for transiently increasing membrane permeabifity, based on the utilization of electric pulses, eventually allowing DNA introduction into the cells. Figures 3 and 4) 
